S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Laser breakthrough could send stock soaring 2,467% (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Laser breakthrough could send stock soaring 2,467% (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Laser breakthrough could send stock soaring 2,467% (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Laser breakthrough could send stock soaring 2,467% (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:BLPH

Bellerophon Therapeutics (BLPH) Stock Forecast, Price & News

$0.94
-6.12 (-86.65%)
(As of 06/5/2023 ET)
Compare
Today's Range
$0.89
$1.34
50-Day Range
$0.94
$12.39
52-Week Range
$0.67
$12.58
Volume
12.91 million shs
Average Volume
1.50 million shs
Market Capitalization
$9.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

Bellerophon Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3,081.3% Upside
$30.00 Price Target
Short Interest
Healthy
2.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.00mentions of Bellerophon Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$5.39 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.18) to ($0.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

328th out of 986 stocks

Pharmaceutical Preparations Industry

146th out of 478 stocks


BLPH stock logo

About Bellerophon Therapeutics (NASDAQ:BLPH) Stock

Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline includes PH-ILD, PH-COPD, INOpulse and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.

Receive BLPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BLPH Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
H.C. Wainwright Reaffirms Their Buy Rating on Bellerophon (BLPH)
See More Headlines

BLPH Price History

BLPH Company Calendar

Last Earnings
3/31/2023
Today
6/05/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLPH
Fax
N/A
Employees
21
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+3,081.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-19,830,000.00
Pretax Margin
-267.06%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.27 per share

Miscellaneous

Free Float
8,015,000
Market Cap
$9.85 million
Optionable
Not Optionable
Beta
0.91

Key Executives

  • Peter Fernandes
    Chief Executive, Financial & Accounting Officer
  • Parag Suresh Shah
    Vice President-Business Operations
  • Martin Dekker
    Vice President-Engineering & Manufacturing
  • Edwin L. Parsley
    Chief Medical Officer
  • Bobae Kim
    VP-Regulatory Affairs & Quality Assurance













BLPH Stock - Frequently Asked Questions

Should I buy or sell Bellerophon Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BLPH shares.
View BLPH analyst ratings
or view top-rated stocks.

What is Bellerophon Therapeutics' stock price forecast for 2023?

2 analysts have issued 1 year price objectives for Bellerophon Therapeutics' stock. Their BLPH share price forecasts range from $30.00 to $30.00. On average, they predict the company's share price to reach $30.00 in the next year. This suggests a possible upside of 3,081.3% from the stock's current price.
View analysts price targets for BLPH
or view top-rated stocks among Wall Street analysts.

How have BLPH shares performed in 2023?

Bellerophon Therapeutics' stock was trading at $0.90 at the start of the year. Since then, BLPH stock has increased by 4.8% and is now trading at $0.9430.
View the best growth stocks for 2023 here
.

When is Bellerophon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our BLPH earnings forecast
.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its quarterly earnings data on Friday, March, 31st. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.05.

When did Bellerophon Therapeutics' stock split?

Bellerophon Therapeutics's stock reverse split on the morning of Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (8.90%), Renaissance Technologies LLC (1.63%), BlackRock Inc. (0.92%), Geode Capital Management LLC (0.92%), State Street Corp (0.29%) and Dimensional Fund Advisors LP (0.13%). Insiders that own company stock include Bobae Kim, Life Science Opportu Puissance, New Mountain Investments Ii, L and Wassim Fares.
View institutional ownership trends
.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $0.94.

How much money does Bellerophon Therapeutics make?

Bellerophon Therapeutics (NASDAQ:BLPH) has a market capitalization of $9.85 million. The biotechnology company earns $-19,830,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The official website for the company is www.bellerophon.com. The biotechnology company can be reached via phone at (908) 574-4770 or via email at btinvestorrelations@bellerophon.com.

This page (NASDAQ:BLPH) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -